A Systematic Narrative Review of the Evidence for Labeling of Natural Health Products and Dietary Supplements

2019 ◽  
Vol 25 (8) ◽  
pp. 777-788 ◽  
Author(s):  
Heather Boon ◽  
Natalie Bozinovski
2010 ◽  
Vol 76 (3) ◽  
pp. 896-904
Author(s):  
Yasmin Hasan ◽  
Diane Schoenherr ◽  
Alvaro A. Martinez ◽  
George D. Wilson ◽  
Brian Marples

2007 ◽  
Vol 69 (3) ◽  
pp. S616-S617
Author(s):  
B. Marples ◽  
D. Schoenherr ◽  
S. Galoforo ◽  
Y. Hasan ◽  
A.A. Martinez ◽  
...  

2013 ◽  
Vol 16 (2) ◽  
pp. 272 ◽  
Author(s):  
Casey Sayre ◽  
Neal Davies

Purpose. Research indicating potentially beneficial bioactivity of flavonoids has produced a market and demand for natural health products and dietary supplements containing flavonoids. Implementation of the Canadian natural health product (NHP) regulations in January of 2004 increased regulation and oversight of NHP manufacture and marketing leading many consumers and clinicians to assume a similar pathway of development and approval to over-the-counter or prescription drugs. Methods. Three stereospecific liquid chromatograph/mass spectrometry (LC/MS) methods were used to assess the flavonoids, liquiritigenin, pinocembrin, and pinostrobin, in selected Canadian licensed NHP’s and US marketed dietary supplements. Results. The present study quantifies bioactive flavonoids in these products and notes variability in flavonoid content. Conclusions. Efficacy and safety of NHP’s and dietary supplements should not be assumed due to differences in criteria for NHP licensure by Health Canada as well as variation of flavonoid content between manufacturers and products with similar indications for use. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.


2021 ◽  
Vol 20 ◽  
pp. 153473542199007
Author(s):  
Siddhartha Sood ◽  
Rahul Jayachandiran ◽  
Siyaram Pandey

Melanoma is the deadliest form of skin cancer in the world with a growing incidence in North America. Contemporary treatments for melanoma include surgical resection, chemotherapy, and radiotherapy. However, apart from resection in early melanoma, the prognosis of patients using these treatments is typically poor. In the past decade, there have been significant advancements in melanoma therapies. Immunotherapies such as ipilimumab and targeted therapies such as vemurafenib have emerged as a promising option for patients as seen in both scientific and clinical research. Furthermore, combination therapies are starting to be administered in the form of polychemotherapy, polyimmunotherapy, and biochemotherapy, of which some have shown promising outcomes in relative efficacy and safety due to their multiple targets. Alongside these treatments, new research has been conducted into the evidence-based use of natural health products (NHPs) and natural compounds (NCs) on melanoma which may provide a long-term and non-toxic form of complementary therapy. Nevertheless, there is a limited consolidation of the research conducted in emerging melanoma treatments which may be useful for researchers and clinicians. Thus, this review attempts to evaluate the therapeutic efficacy of current advancements in metastatic melanoma treatment by surveying new research into the molecular and cellular basis of treatments along with their clinical efficacy. In addition, this review aims to elucidate novel strategies that are currently being used and have the potential to be used in the future.


Sign in / Sign up

Export Citation Format

Share Document